Termination of early human pregnancy with RU 486 (mifepristone) and the prostaglandin analogue sulprostone: a multicentre, randomized comparison between two treatment regimens. Hum Reprod 1989;4:718-25. Design-Double blind, randomised controlled trial oftreatment over six weeks.
Introduction
Large scale prospective studies have shown that antihypertensive drugs prevent cardiovascular morbidity and reduce cardiovascular mortality.' 1, Blockers and calcium entry blockers are both recommended as first line treatment for hypertension2 but there are no guidelines about which drugs lower blood pressure most effectively in patients with uncomplicated essential hypertension. Age has been claimed to be an important predictor of response to antihypertensive drugs, but other studies have not confirmed this initial hypothesis or its clinical implications. 4 Obesity, which is present in more than half of hypertensive patients, has been neglected as a potential determinant ofresponse to treatment. 2 Obesity has a major influence on the haemodynamic changes associated with hypertension. 5 Several studies indicate that obese hypertensive patients have a higher cardiac output and lower total peripheral resistance than lean patients at any given level of arterial hypertension.67 Obese hypertensive patients seem to have increased sympathetic activity, which may be reduced with weight loss.8 Different haemodynamic pattems in hypertensive patients have been suggested to be clinically relevant for treating hypertensive patients. 9 We therefore tested the hypothesis that a 3 blocker is more effective than a calcium entry blocker in obese patients and that a calcium entry blocker is more effective than a Pi blocker in lean patients. We reasoned that the putatively hyperdynamic circulation of obese patients would respond better to ,B blockade and that the increased peripheral vascular resistance in lean hypertensive patients might respond better to the smooth muscle relaxing effects of a calcium entry blocking drug.' l-'2
Subjects and methods
Patients referred to our hospital because of arterial hypertension were consecutively enrolled if they fulfilled all the study criteria. to be taken. No drug was detected in blood from one patient in the isradipine group and from five patients in the metoprolol group. These six patients were excluded from the statistical analysis (non-compliant patients). None of the patients was lost to follow up and no serious side effects were encountered. The protocol was approved by the institutional committee on human subjects. Written, informed consent was obtained from each patient before the run in phase.
The results were analysed on an IBM 308-1 computer system with the SPSS-X statistical program."3 Thirty six patients were entered in the data analysis. They were stratified according to treatment and according to absence or presence of obesity. Subjects were classified as lean if their body mass index ranged was 19-27 kg/mi and as obese if body mass index was greater than 27 kg/ mi2. The cut off point of 27 kg/M2 was chosen according to the results of the National Center for Health Statistics survey.'4 Furthermore 27 kg/mi corresponds closely to the criterion for obesity suggested in the 1983 Metropolitan Life Insurance tables (> 20% over desirable weight for people of medium build)." Analysis of variance was used to compare the response after six weeks of treatment, with age and systolic and diastolic blood pressure before treatment as cofactors. Unless otherwise specified, the data are expressed as mean (SD).
Results
Patients in the two treatment groups did not differ in age (47 (10) in ,B blocker group v 50 (11) years in calcium entry blocker group), heart rate (79 (8) v 77 (7) beats/min), and blood pressure before treatment (161 (8)/104 (7) v 162 (14)/102 (7) mm Hg). Furthermore, (17) 137 (14) 141 (10) Two way interaction of obesity and drug therapy, p-0-019. Obese (>27 kg/m') 24-0 (12-5) 16-3 to 31-6 18-2 (11-0) 10-5 to Two way interaction of obesity and drug therapy, NS.
when both treatment groups were stratified into lean and obese groups, the four patient groups were similar with respect to age and blood pressure before treatment, both of which can influence the decrease in blood pressure in response to antihypertensive treatment (table I) . No significant change in weight was observed in any of the four groups throughout the study period of six weeks ( blocker or calcium entry blockers. We found that the decrease in diastolic blood pressure was more pronounced in obese hypertensive patients receiving the ,B blocker metoprolol than in those receiving the calcium entry blocker isradipine. In lean patients isradipine was more effective than metoprolol at reducing blood pressure. This significant interaction between body weight and drug treatment was masked behind the fact that neither obesity nor drug therapy alone emerged as determinants for the decrease in diastolic blood pressure with treatment.
Studies examining the antihypertensive response to drugs suggested age,34 several humoral factors,"6"7 or sodium excretion'8 as potential determinants for the fall in blood pressure with treatment. However, these studies did not discuss the effect of obesity.2 19 Several classes of antihypertensive drugs have been suggested to be particularly effective in obese patients, including sympatholytic agents, calcium entry blockers, and converting enzyme inhibitors.8 20 Controlled trials have been performed in groups of obese subjects. Clonidine was found to be less efficacious than the hydrochlorothiazide.21 But in another study clonidine was compared with placebo in obese patients and was found to effectively lower both blood pressure and plasma noradrenaline concentrations."
We randomised obese and lean hypertensive patients to receive either a i blocker or a calcium entry blocker and were thus able to test for interactions not only related to drug effect but also related to the presence or absence of obesity. Our data suggested that the likelihood of good blood pressure control was increased when metoprolol was given to obese patients and isradipine to lean patients. The large standard deviation in lean patients given ,B blocker and obese patients given calcium entry blocker suggests that the individual response to treatment was highly variable.
LIMITATIONS OF THE STUDY
Certain critical points of our study need to be addressed to facilitate the interpretation of our results. We included only a small number of subjects, but this limitation is counterbalanced to a degree by the double blind, randomised controlled design. We were also able to determine drug compliance accurately by measuring drug serum concentrations. Whether different pharmacokinetic properties (for instance distribution volume) of the drugs have affected our results remains unknown. Nevertheless serum drug concentrations are only poorly related to the antihypertensive effects of antihypertensive drugs.' By randomising and enrolling only patients with uncomplicated mild to moderate essential hypertension we obtained four groups of subjects that were similar in age and in blood pressure before treatment. Both age and blood pressure are potential determinants of the response to antihypertensive treatment.34 The effects on blood pressure were assessed after six weeks of treatment, with a single titration of dose at about Clinical implications 0 * Obese patients with hypertension have high cardiac output and low total peripheral resistance * This study showed that obesity is a determinant of the initial antihypertensive response to drugs independent of age and blood pressure before treatment * In obese hypertensive patients ,B blockers reduced high blood pressure more effectively than calcium entry blockers did * In lean hypertensive patients calcium entry blockers controlled high blood pressure better than ,B blockers did * Obesity should be considered when deciding on treatment for hypertension three weeks. We cannot predict whether the interaction between drug treatment and obesity would be still evident after longer treatment.
Finally, our data cannot necessarily be applied to all 13 blockers and all calcium entry blockers. 
CONCLUSIONS
In summary, our study showed that obesity influenced the efficacy of certain antihypertensive drugs. The I blocker metoprolol lowered blood pressure more effectively in obese patients, while the calcium entry blocker isradipine was more effective in lean patients. More clinical studies will be needed to confirm our findings and extend these observations to other hypertensive drugs. Such studies are necessary to provide general guidelines for rational treatment of hypertension.
We thank Friedrich C Luft for critical review of this manuscript. Dramatic improvement followed treatment with sulphasalazine and oral corticosteroids. A year later there was a fiuther relapse, but no improvement was observed despite administration of corticosteroids in high dosage. Barium enema showed that nearly all of the colon was affected. Serum alkaline phosphatase activity was 18-8 units (King-Armstrong method) and a liver biopsy specimen showed pericholangitis. His blood urea concentration ranged from 10-0 mmoUl to 16-6 mmol/l, and creatinine clearance was further reduced to 14-15 mlmin. A renal biopsy specimen showed chronic interstitial nephritis with local periglomerulofibrosis and granuloma formation (figure). A chest x ray film was normal; no tubercle bacilli were present in the urine. A Kveim test gave negative results, and the results of brucella serology were also negative. The patient's condition progressively deteriorated, with a rise in blood urea concentration to 19 9 mmol/. Proctocolectomy was performed. He had an uneventfuil recovery and was discharged in good general condition without needing to be prescribed drugs.
Four years later he was still in remission with no specific treatment. His blood urea concentration had fallen to 9 1 mmol/l and his creatinine clearance increased to 29 mlmin. A second renal biopsy specimen showed mesangial prominence, loss and atrophy of renal tubules, and local interstitial fibrosis; no granulomas were found.
Comment
Liver granulomas occur in about 9 5% of patients with Crohn's disease,' although clinically overt liver involvement does not seem to be present in more than 2% of patients.3 To our knowledge, the presence of renal granulomas in patients with Crohn's disease has not been described before. It should be pointed out that granuloma formation in the kidneys is uncommon but may occur in tuberculosis, sarcoidosis, brucellosis, Wegener's granulomatosis, xanthogranulomatous pyelonephritis, malacoplakia, leprosy, and toxoplasmosis and as an adverse reaction to various drugs. 4' In our case all these causes of granuloma formation could reasonably be excluded from the patient's history; sulphasalazine, which may cause many untoward reactions such as haemolytic anaemia, temporal arteritis, and systemic lupus erythromatosus, was used only after the renal impairment was discovered. In addition, the beneficial effect of proctocolectomy on renal function and the disappearance of
